1. The invention is (I) a derivative of pyridine pyridine, which conforms to the formula of (I), wherein R1 is a hydrogen atom or a hydrocarbon (C1-C4)；R2 represents a population - (CH2) n '- B where n' = 0, 1, 2, 3 or 4 and B represents a cyclopentyl (C3-C5),1. One asphalt group (C1-C4) or one alcox group (C1-C4)；Y. Z, V and W represent an independent groupA carbon atom1. Non atom or non atom, it should be understood that the cycle including V, W, y and Z is a cycle with 5 to 6 links, but it is understood that the dotted line in the cycle indicates that the generated cycle is an aromatic cycle, and the cycle should be understood as including 0, 1 or 2 non atoms； R3 and R4 represent each other,a. The same or different group selected from the hydrogen atom and the linear tar group (C1-C4), or formed a cyclopentyl compound group (C3-C5) together with carbon；M integer is equal to 1, 2, 3 or 4； R5 represents hydrogen atom or tar group (C1-C4)；R6 represents an n-l group, n = 0, 1, 2 or 3, and l is a group selected from arilos of six carbon atoms, which are heterogeneous of five to six carbon atoms, heterogeneous saturation cycle composed of five, six or seven carbon atoms, or formed together with nitrogen atoms and connected with a heterogeneous group, (II) prepare and (III) use for therapeutic purposes to inhibit kunsa activity in PDGFs alliance recipients and / or FLT3 alliance recipients.La invención se refiere (i) a derivados de piridino - piridinonas que responden a la fórmula (I): en la que R1 representa un átomo de hidrógeno o un grupo alquilo (C1 - C4)； R2 representa un grupo - (CH2) n' - B donde n' = 0, 1, 2, 3 o 4 y B representa un grupo cicloalquilo (C3 - C5), un grupo alquilo (C1 - C4) o un grupo alcoxi (C1 - C4) ； Y, Z, V y W representan independientemente entre sí un grupo -CH-, un átomo de carbono , un heteroátomo o ausencia de átomo, entendiéndose que el ciclo, en el que están comprendidos V, W, Y y Z es un ciclo que comprende 5 o 6 eslabones, entendiéndo
